stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) EBITDA
MBX Biosciences, Inc.'s EBITDA for fiscal 2025 was −$97.8M, compared with −$68.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$117.7M. EBITDA has fallen for 3 consecutive fiscal years. MBX Biosciences, Inc. ranks 443rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$97.8M | — |
| FY2024 | −$68.0M | — |
| FY2023 | −$35.2M | — |
| FY2022 | −$25.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$40.9M | — |
| Mar 2026 | −$27.2M | — |
| Dec 2025 | −$25.7M | — |
| Sep 2025 | −$23.9M | — |
| 7 more quarters | Free account |
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| MBX MBX Biosciences, Inc. | −$117.7M |
| XNCR Xencor, Inc. compare | −$209.4M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$253.7M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
| RCUS Arcus Biosciences, Inc. compare | −$488.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item